{"id":"canakinumab-injection","safety":{"drugInteractions":[{"drug":"Abatacept","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Anakinra","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Bacillus Calmette-Guérin (BCG) vaccine","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Other vaccines","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Tofacitinib","action":"Monitor","effect":"Increased risk of infections"}],"commonSideEffects":[{"effect":"General AE","drugRate":"92.9%","placeboRate":"","totalAtRisk":28,"totalAffected":26,"trialsReporting":1},{"effect":"Acute Kidney Injury","drugRate":"26.7%","placeboRate":"","totalAtRisk":15,"totalAffected":4,"trialsReporting":1},{"effect":"Anemia","drugRate":"26.7%","placeboRate":"","totalAtRisk":15,"totalAffected":4,"trialsReporting":1},{"effect":"Acute respiratory distress syndrome","drugRate":"20.0%","placeboRate":"","totalAtRisk":15,"totalAffected":3,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"50.0%","placeboRate":"","totalAtRisk":4,"totalAffected":2,"trialsReporting":1},{"effect":"Bronchitis","drugRate":"50.0%","placeboRate":"","totalAtRisk":4,"totalAffected":2,"trialsReporting":1},{"effect":"Conjunctivitis","drugRate":"50.0%","placeboRate":"","totalAtRisk":4,"totalAffected":2,"trialsReporting":1},{"effect":"Gastroenteritis","drugRate":"50.0%","placeboRate":"","totalAtRisk":4,"totalAffected":2,"trialsReporting":1},{"effect":"Drug eruption","drugRate":"50.0%","placeboRate":"","totalAtRisk":4,"totalAffected":2,"trialsReporting":1},{"effect":"Hypertension","drugRate":"10.5%","placeboRate":"","totalAtRisk":19,"totalAffected":2,"trialsReporting":2},{"effect":"Arrhythmia","drugRate":"13.3%","placeboRate":"","totalAtRisk":15,"totalAffected":2,"trialsReporting":1},{"effect":"Elevated Ferritin","drugRate":"13.3%","placeboRate":"","totalAtRisk":15,"totalAffected":2,"trialsReporting":1},{"effect":"Elevated CRP","drugRate":"13.3%","placeboRate":"","totalAtRisk":15,"totalAffected":2,"trialsReporting":1},{"effect":"Hypoxia","drugRate":"13.3%","placeboRate":"","totalAtRisk":15,"totalAffected":2,"trialsReporting":1},{"effect":"Delirium","drugRate":"13.3%","placeboRate":"","totalAtRisk":15,"totalAffected":2,"trialsReporting":1},{"effect":"Positive Respiratory Culture","drugRate":"13.3%","placeboRate":"","totalAtRisk":15,"totalAffected":2,"trialsReporting":1},{"effect":"Worsening D-Dimer","drugRate":"13.3%","placeboRate":"","totalAtRisk":15,"totalAffected":2,"trialsReporting":1},{"effect":"Fever","drugRate":"13.3%","placeboRate":"","totalAtRisk":15,"totalAffected":2,"trialsReporting":1},{"effect":"Tachycardia","drugRate":"5.3%","placeboRate":"","totalAtRisk":19,"totalAffected":1,"trialsReporting":2},{"effect":"Familial mediterranean fever","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Hyper IgD syndrome","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Eye allergy","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Eye pain","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Scleritis","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Aphthous ulcer","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Constipation","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Dental caries","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Gastritis","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Haemorrhoids","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Nausea","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Stomatitis","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Teething","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Vomiting","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Malaise","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Ear infection","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Influenza","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Pneumonia","drugRate":"5.3%","placeboRate":"","totalAtRisk":19,"totalAffected":1,"trialsReporting":2},{"effect":"Rhinitis","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Sialoadenitis","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Tonsillitis bacterial","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Viral tonsillitis","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Viral upper respiratory tract infection","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Wound","drugRate":"5.3%","placeboRate":"","totalAtRisk":19,"totalAffected":1,"trialsReporting":2},{"effect":"Alanine aminotransferase increased","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Aspartate aminotransferase increased","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"C-reactive protein increased","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Neutrophil count decreased","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1},{"effect":"Neutrophil count increased","drugRate":"25.0%","placeboRate":"","totalAtRisk":4,"totalAffected":1,"trialsReporting":1}],"contraindications":["ILARIS is contraindicated in patients with confirmed hypersensitivity to canakinumab or to any of the excipients."],"specialPopulations":{"Pregnancy":"Talk with the doctor if your child is pregnant, becomes pregnant, or is breast-feeding a baby. You will need to talk about the benefits and risks to your child and the baby. If your child used this drug while pregnant, tell the baby’s doctor.","Geriatric use":"text not available","Paediatric use":"It is used to treat Still’s Disease. It may be given to your child for other reasons. Talk with the doctor.","Renal impairment":"text not available","Hepatic impairment":"text not available"},"seriousAdverseEvents":[]},"company":"Pfizer","_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T21:33:28.474375+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T21:33:48.661994+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201834/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T21:33:22.254303+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:33:50.001533+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:33:21.359217+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:33:50.001505+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:33:50.001502+00:00"},"commercial.annualRevenue":{"url":"","method":"deterministic","source":"SEC EDGAR 10-K","rawText":"$372M FY2025","confidence":0.8,"sourceType":"sec_edgar","retrievedAt":"2026-04-19T21:33:28.474411+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:33:50.001437+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:33:50.001479+00:00"}},"allNames":"canakinumab injection","timeline":[],"aiSummary":"Canakinumab Injection, developed by Pfizer, holds a significant market position with annual revenues of $372M and is indicated for five inflammatory conditions. Its competitive advantage lies in its specific mechanism as a monoclonal antibody targeting IL-1β, distinguishing it from alternatives like Colchicine, Indomethacin, Naproxen, Ibuprofen, and Methylprednisolone, which are primarily used for gout treatment. A key risk is the requirement for a PD-L1 companion diagnostic for several of its indications, which may limit its accessibility and broaden its application challenges. Despite no ongoing clinical trials, the established revenue and multiple approved indications suggest a stable pipeline outlook.","brandName":"Canakinumab Injection","isGeneric":true,"mechanism":{"target":"IL-1β","novelty":"Best-in-class","modality":"Monoclonal Antibody","drugClass":"Monoclonal Antibody","explanation":"Canakinumab Injection is a monoclonal antibody that targets and neutralizes interleukin-1 beta (IL-1β), a key cytokine involved in the inflammatory process. This targeted approach provides a more precise and effective treatment approach compared to traditional anti-inflammatory medications. By neutralizing IL-1β, Canakinumab Injection reduces inflammation and prevents the progression of various inflammatory conditions.","oneSentence":"Canakinumab Injection is a monoclonal antibody that targets and neutralizes interleukin-1 beta (IL-1β) to treat inflammatory conditions.","technicalDetail":"Canakinumab Injection is a recombinant humanized IgG1κ monoclonal antibody that binds to IL-1β with high affinity, preventing its interaction with the IL-1 receptor. This leads to a reduction in inflammation and a decrease in the production of pro-inflammatory cytokines. The drug's mechanism of action is well-established, with a clear understanding of its effects on the immune system."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL1201834","maxPhase":"4.0","chirality":1,"parenteral":true,"availability":1,"moleculeType":"Antibody","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":372,"genericStatus":"Biologic — patent protected","revenueSource":"SEC 8-K Novartis (2024-10-29)","currentRevenue":"$21.2B","revenueCurrency":"USD","peakSalesEstimate":"$21.2B","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:46.193324","revenueExtractedBy":"revenue-sec"},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=canakinumab-injection","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=canakinumab-injection","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:45:11.655723+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"competitors":[{"name":"Colchicine","company":"Colcrys","advantage":"Effective for preventing gout flares in adults"},{"name":"Indomethacin","company":"Indocin","advantage":"Competes as an alternative for gout treatment"},{"name":"Naproxen","company":"Naprosyn","advantage":"Competes as an alternative for gout treatment"},{"name":"Ibuprofen","company":"Advil","advantage":"Competes as an alternative for gout treatment"},{"name":"Methylprednisolone","company":"Medrol","advantage":"Competes as an alternative for gout treatment"},{"name":"Ilaris","company":"Ilaris","advantage":"Competes as an alternative for Familial Mediterranean Fever treatment"},{"name":"Actemra","company":"Actemra","advantage":"Competes as an alternative for Familial Mediterranean Fever treatment"}],"genericName":"canakinumab-injection","indications":{"approved":[{"name":"Prophylaxis of gouty arthritis attacks in adults","regulator":"FDA"},{"name":"Prophylaxis of gouty arthritis attacks in pediatric patients 2 years of age and older","regulator":"FDA"},{"name":"Treatment of cryopyrin-associated periodic syndromes (CAPS) in adults and children 4 months of age and older","regulator":"FDA"},{"name":"Treatment of systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older","regulator":"FDA"},{"name":"Treatment of Familial Mediterranean Fever (FMF) in adults and children 4 months of age and older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"trialDetails":[],"_emaApprovals":[{"date":"","name":"Canakinumab Injection","status":"Authorised","regulator":"EMA"}],"molecularData":{"oral":false,"chemblId":"CHEMBL1201834","moleculeType":"Antibody","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL1201834"},"_offLabelChecked":true,"chemblMechanisms":[{"actionType":"INHIBITOR","targetChemblId":"CHEMBL1909490","mechanismComment":null,"mechanismOfAction":"Interleukin-1 beta inhibitor"}],"publicationCount":7,"_revenueScrapedAt":"2026-04-01 10:47:45.503507+00","recentPublications":[{"date":"2006","pmid":"29999640","title":"Canakinumab.","journal":""},{"date":"2023","pmid":"37854599","title":"Case Report: A de novo NLRP3 variant resulting in autoinflammatory disease in a Chinese newborn.","journal":"Frontiers in immunology"},{"date":"2020 Jun 16","pmid":"32546242","title":"Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.","journal":"Pediatric rheumatology online journal"},{"date":"2020 Jul-Aug","pmid":"32324125","title":"Cutaneous manifestations in mevalonate kinase deficient patients treated with canakinumab.","journal":"Clinical and experimental rheumatology"},{"date":"2020 Jan","pmid":"31273456","title":"Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.","journal":"Rheumatology international"}],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"_genericFilersChecked":true,"structuredTrialResults":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":8,"withResults":3},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:45:11.655723+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}